Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8453702 | Lung Cancer | 2018 | 21 Pages |
Abstract
Patients who were treated for stage IV NSCLC at highest-volume facilities had less risk of all-cause mortality compared with those who were treated at lower-volume facilities. Although the survival advantage of being treated at highest-volume facilities appeared small, the results of this study suggest differences in cancer care delivery models among various facilities, and may become more relevant in the future era of personalized treatment of stage IV NSCLC.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gaurav Goyal, Anuhya Kommalapati, Adam C. Bartley, Tina M. Gunderson, Alex A. Adjei, Ronald S. Go,